Semaglutide, the active ingredient in Ozempic and Wegovy, activates only the GLP-1 receptor
The body can also experience skin laxity, stubborn fat pockets, and diminished tone

1,4 Adverse events 5% in SUSTAIN 5 8,10 AEs occurring in 5% of participants treated with Ozempic injection in SUSTAIN 5 Incidence of severe hypoglycemia was 1.5% across all placebo-controlled trials 1 Incidence of severe hypoglycemia or blood glucose-confirmed hypoglycemia (% of patients) was 8,10 : 8.3% with Ozempic 0.5 mg + basal insulin MET 10.7% with Ozempic 1 mg + basal insulin MET 5.3% with placebo + basal insulin MET Patients receiving Ozempic injection in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia 1 Adverse events 5% in SUSTAIN FORTE 4 AEs occurring in 5% of patients receiving Ozempic injection 1 mg and 2 mg in SUSTAIN FORTE In placebo-controlled trials, the most common adverse reactions reported in 5% of patients treated with Ozempic injection are nausea, vomiting, diarrhea, abdominal pain, and constipation 1 No new safety signals were identified

Less effective than the injectable options and comes with gastrointestinal side effects that most people find difficult to manage long term
PlexusDx's Precision Peptide Genetic Test ($298) analyzes 14 metabolic pathways and 49 peptides, including GIPR variants that influence how strongly your gut responds to tirzepatide
This isnt a one-size-fits-all weight loss clinic